Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Anticoagulation

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02427516

CV185-374

Details and patient eligibility

About

To estimate annualized total cost rates (i.e. direct medical costs from hospitalizations, consultations, medications, and tests) of adequately controlling a patient (i.e. INR between 2-3 and TTR≥ 60%) diagnosed with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE), and treated with vitamin K antagonists (VKA) in Spain.

Enrollment: 1,144 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Patients aged 18 or older over the study period
• Patients with a diagnosis for NVAF or VTE anytime in their medical records
• Patients having at least one year of enrolment in the database prior to the index date
• Patients newly initiated with VKA during the study period (index date)

Exclusion Criteria:

• Patients with a diagnosis for both NVAF and VTE anytime in their medical records

Trial design

1,144 participants in 2 patient groups

NVAF-VKA cohort

Description:

NVAF patients who initiate a VKA treatment

VTE-VKA cohort

Description:

VTE patients who initiate a VKA treatment